tradingkey.logo

Affinia Therapeutics Granted FDA Fast Track Designation For Aftx-201 As A Treatment For People Living With Bag3-Associated Dilated Cardiomyopathy (Dcm)

ReutersMar 4, 2026 12:45 PM

- Affinia Therapeutics Inc AFTX.O:

  • AFFINIA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR AFTX-201 AS A TREATMENT FOR PEOPLE LIVING WITH BAG3-ASSOCIATED DILATED CARDIOMYOPATHY (DCM)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI